Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 13/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 0.70 |
| ▸ | JAK3 | P52333 | 1/20 | 0.70 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.54 |
| ▸ | IDH1 | O75874 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7017465 | 0.94 | LCK (0.89) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7016983 | 0.93 | LCK (0.87) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7585859 | 0.92 | LCK (0.84) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7020633 | 0.92 | LCK (0.84) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7018018 | 0.92 | LCK (0.84) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7027225 | 0.92 | LCK (0.84) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7590479 | 0.92 | LCK (0.84) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7018013 | 0.92 | LCK (0.84) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7590066 | 0.92 | LCK (0.84) | LCKJAK2JAK3MKNK1MKNK2 | |
| SCHEMBL7015182 | 0.90 | LCK (0.82) | LCKJAK2JAK3MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |